Tarsus Pharmaceuticals, Inc. - Common Stock (TARS)
CUSIP: 87650L103
Q3 2025 13F Holders as of 30 Sep 2025
- Type / Class
- Equity / Common Stock
- Shares outstanding
- 42,450,857
- Total 13F shares
- 44,893,892
- Share change
- -1,293,631
- Total reported value
- $2,667,774,204
- Put/Call ratio
- 31%
- Price per share
- $59.43
- Number of holders
- 219
- Value change
- -$49,024,662
- Number of buys
- 100
- Number of sells
- 115
Quarterly Holders Quick Answers
What is CUSIP 87650L103?
CUSIP 87650L103 identifies TARS - Tarsus Pharmaceuticals, Inc. - Common Stock in SEC institutional holdings data.
Need full ownership history?
Open the full security ownership history page.
Next holder-history checks
These links keep the next click tied to holder verification, nearby quarters, or outside-13F ownership context.
- Back to full security ownership history for the broader multi-quarter picture.
- Latest 13F filings for newly reported positions across managers.
- Latest Schedule 13D/13G reports for ownership changes outside the 13F cadence.
- SEC investors directory for manager drilldown.
Explore More Reporting Periods
Jump to adjacent filing periods for faster comparison and easier crawl discovery.
Recent filing periods for CUSIP 87650L103:
Top shareholders of TARS - Tarsus Pharmaceuticals, Inc. - Common Stock (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Ownership % is shown only when it is directly reported or safely comparable across share classes.
Methodology: rows are grouped by holder and ranked by the holder's primary source value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
| Holder | Source | Role / Reporting | Ownership % | Shares | Holdings Value | 12M Net Δ | As of | Details |
|---|---|---|---|---|---|---|---|---|
| Deep Track Capital, LP |
13D/G
13F
|
Company |
7.1%
|
3,000,000
|
$178,290,000 | +$38,453,587 | 30 Sep 2025 | |
| BlackRock, Inc. |
13D/G
13F
|
Company |
7.4%
|
3,092,735
|
$153,770,784 | $0 | 31 Mar 2025 | |
| RTW INVESTMENTS, LP |
13D/G
3/4/5
13F
|
10%+ Owner · Company |
8.1%
|
3,424,180
|
$134,159,372 | $0 | 30 Jun 2025 | |
| Paradigm Biocapital Advisors LP |
13F
|
Company |
7%
|
2,976,099
|
$120,561,770 | — | 30 Jun 2025 | |
| JENNISON ASSOCIATES LLC |
13F
|
Company |
5.8%
|
2,467,998
|
$99,978,600 | — | 30 Jun 2025 | |
| TANG CAPITAL MANAGEMENT LLC |
13F
|
Company |
5.8%
|
2,454,797
|
$99,443,826 | — | 30 Jun 2025 | |
| MORGAN STANLEY |
13D/G
13F
|
Company |
4.7%
|
1,943,453
|
$96,628,483 | $0 | 31 Mar 2025 | |
| Cowen Financial Products LLC |
13D/G
|
— |
4.9%
|
1,909,228
|
$94,926,816 | $0 | 31 Dec 2024 | |
| VANGUARD GROUP INC |
13F
|
Company |
5.4%
|
2,297,354
|
$93,065,810 | — | 30 Jun 2025 | |
| JANUS HENDERSON GROUP PLC |
13F
|
Company |
4.3%
|
1,806,947
|
$73,236,456 | — | 30 Jun 2025 | |
| Frazier Life Sciences Management, L.P. |
13F
|
Company |
3.3%
|
1,397,527
|
$56,613,819 | — | 30 Jun 2025 | |
| Vivo Capital IX, LLC |
3/4/5
|
10%+ Owner |
—
class O/S missing
|
2,469,001
|
$49,380,020 | — | 05 May 2022 | |
| TORONTO DOMINION BANK |
13F
|
Company |
2.4%
|
1,001,962
|
$40,589,481 | — | 30 Jun 2025 | |
| Assenagon Asset Management S.A. |
13F
|
Company |
2.3%
|
997,587
|
$40,412,249 | — | 30 Jun 2025 | |
| LORD, ABBETT & CO. LLC |
13F
|
Company |
2.3%
|
995,425
|
$40,325,000 | — | 30 Jun 2025 | |
| STATE STREET CORP |
13F
|
Company |
2.3%
|
980,868
|
$39,734,963 | — | 30 Jun 2025 | |
| MACQUARIE GROUP LTD |
13F
|
Company |
2.2%
|
948,850
|
$38,438,000 | — | 30 Jun 2025 | |
| GEODE CAPITAL MANAGEMENT, LLC |
13F
|
Company |
2.2%
|
934,420
|
$37,858,822 | — | 30 Jun 2025 | |
| Invesco Ltd. |
13F
|
Company |
2.2%
|
928,501
|
$37,613,575 | — | 30 Jun 2025 | |
| DRIEHAUS CAPITAL MANAGEMENT LLC |
13F
|
Company |
2.1%
|
876,547
|
$35,508,919 | — | 30 Jun 2025 | |
| D. E. Shaw & Co., Inc. |
13F
|
Company |
1.7%
|
723,183
|
$29,296,143 | — | 30 Jun 2025 | |
| ADAGE CAPITAL PARTNERS GP, L.L.C. |
13F
|
Company |
1.3%
|
543,000
|
$21,996,930 | — | 30 Jun 2025 | |
| Artisan Partners Limited Partnership |
13F
|
Company |
1.3%
|
539,303
|
$21,847,165 | — | 30 Jun 2025 | |
| Ensign Peak Advisors, Inc |
13F
|
Company |
1.1%
|
487,310
|
$19,740,928 | — | 30 Jun 2025 | |
| NORGES BANK |
13F
|
Company |
1.1%
|
471,354
|
$19,094,551 | — | 30 Jun 2025 | |
| BANK OF AMERICA CORP /DE/ |
13F
|
Company |
1.1%
|
466,280
|
$18,889,003 | — | 30 Jun 2025 | |
| Qube Research & Technologies Ltd |
13F
|
Company |
1.1%
|
459,436
|
$18,611,752 | — | 30 Jun 2025 | |
| Clearbridge Investments, LLC |
13F
|
Company |
1%
|
444,502
|
$18,006,793 | — | 30 Jun 2025 | |
| GOLDMAN SACHS GROUP INC |
13F
|
Company |
0.94%
|
397,994
|
$16,122,737 | — | 30 Jun 2025 | |
| PRICE T ROWE ASSOCIATES INC /MD/ |
13F
|
Company |
0.9%
|
383,902
|
$15,553,000 | — | 30 Jun 2025 | |
| Rock Springs Capital Management LP |
13F
|
Company |
0.88%
|
373,750
|
$15,140,613 | — | 30 Jun 2025 | |
| J. Goldman & Co LP |
13F
|
Company |
0.86%
|
364,557
|
$14,768,204 | — | 30 Jun 2025 | |
| NORTHERN TRUST CORP |
13F
|
Company |
0.84%
|
357,178
|
$14,469,280 | — | 30 Jun 2025 | |
| MPM BioImpact LLC |
13F
|
Company |
0.8%
|
341,496
|
$13,834,003 | — | 30 Jun 2025 | |
| Nuveen, LLC |
13F
|
Company |
0.79%
|
336,939
|
$13,649,400 | — | 30 Jun 2025 | |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC |
13F
|
Company |
0.78%
|
329,297
|
$13,339,821 | — | 30 Jun 2025 | |
| Cormorant Asset Management, LP |
13F
|
Company |
0.71%
|
300,000
|
$12,153,000 | — | 30 Jun 2025 | |
| Tetragon Partners GP Ltd |
13F
|
Company |
0.59%
|
250,000
|
$10,127,500 | — | 30 Jun 2025 | |
| Capitolis Liquid Global Markets LLC |
13F
|
Company |
0.57%
|
242,100
|
$9,807,471 | — | 30 Jun 2025 | |
| Jump Financial, LLC |
13F
|
Company |
0.56%
|
237,117
|
$9,605,610 | — | 30 Jun 2025 | |
| CITADEL ADVISORS LLC |
13F
|
Company |
0.54%
|
229,246
|
$9,286,755 | — | 30 Jun 2025 | |
| Integral Health Asset Management, LLC |
13F
|
Company |
0.47%
|
200,000
|
$8,102,000 | — | 30 Jun 2025 | |
| ORBIMED ADVISORS LLC |
13F
|
Company |
0.47%
|
197,900
|
$8,016,929 | — | 30 Jun 2025 | |
| Ikarian Capital, LLC |
13F
|
Company |
0.46%
|
196,536
|
$7,961,673 | — | 30 Jun 2025 | |
| ROYAL BANK OF CANADA |
13F
|
Company |
0.45%
|
189,549
|
$7,679,000 | — | 30 Jun 2025 | |
| PRUDENTIAL FINANCIAL INC |
13F
|
Company |
0.43%
|
182,400
|
$7,389,024 | — | 30 Jun 2025 | |
| Tri Locum Partners LP |
13F
|
Company |
0.42%
|
177,656
|
$7,196,845 | — | 30 Jun 2025 | |
| Sands Capital Alternatives, LLC |
13F
|
Company |
0.4%
|
170,000
|
$6,886,700 | — | 30 Jun 2025 | |
| Jefferies Financial Group Inc. |
13F
|
Company |
0.38%
|
162,996
|
$6,602,968 | — | 30 Jun 2025 | |
| BNP PARIBAS FINANCIAL MARKETS |
13F
|
Company |
0.36%
|
152,309
|
$6,170,038 | — | 30 Jun 2025 |
Institutional Holders of Tarsus Pharmaceuticals, Inc. - Common Stock (TARS) as of Q3 2025
As of 30 Sep 2025,
Tarsus Pharmaceuticals, Inc. - Common Stock (TARS) was held by
219 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
44,893,892 shares.
The largest 10 holders included
BlackRock, Inc., RTW INVESTMENTS, LP, Deep Track Capital, LP, Paradigm Biocapital Advisors LP, JENNISON ASSOCIATES LLC, TANG CAPITAL MANAGEMENT LLC, VANGUARD GROUP INC, MORGAN STANLEY, JANUS HENDERSON GROUP PLC, and Assenagon Asset Management S.A..
This page lists
219
institutional shareholders reporting positions in this security
for the Q3 2025 filing period.
| Investor | Option | Weight % | Change % | Value $ | * Price | Shares | Share Change | Activity | Report Period |
|---|
Compare Q3 2025 vs Q2 2025 Across Filers
Q2 2025 holders
204
Q3 2025 holders
219
Holder diff
15
| Investor | Q2 2025 Shares | Q3 2025 Shares | Share Diff | Share Chg % | Q2 2025 Value $ | Q3 2025 Value $ | Value Diff $ | Value Chg % |
|---|
Trend: ostatnie 8 kwartałów (+ wybrane okresy porównania).
Quarterly Holders Trend
Quarterly Value Trend
Quarterly Shares Trend
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.
An asterisk sign (*) next to the price indicates that the price is likely invalid.